The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 27 of the 37 sources its claims cite were checked for support.
Association of SPI1 Haplotypes with Altered SPI1 Gene Expression and Alzheimer’s Disease Risk
Open accessAbstract
BACKGROUND: Genetic studies reveal that single-nucleotide polymorphisms (SNPs) of SPI1 are associated with Alzheimer's disease (AD), while their effects in the Chinese population remain unclear. OBJECTIVE: We aimed to examine the AD-association of SPI1 SNPs in the Chinese population and investigate the underlying mechanisms of these SNPs in modulating AD risk. METHODS: We conducted a genetic analysis of three SPI1 SNPs (i.e., rs1057233, rs3740688, and rs78245530) in a Chinese cohort (n = 333 patients with AD, n = 721 normal controls). We also probed public European-descent AD cohorts and gene expression datasets to investigate the putative functions of those SNPs. RESULTS: We showed that SPI1 SNP rs3740688 is significantly associated with AD in the Chinese population (odds ratio [OR] = 0.72 [0.58-0.89]) and identified AD-protective SPI1 haplotypes β (tagged by rs1057233 and rs3740688) and γ (tagged by rs3740688 and rs78245530). Specifically, haplotypes β and γ are associated with decreased SPI1 gene expression level in the blood and brain tissues, respectively. The regulatory roles of these haplotypes are potentially mediated by changes in miRNA binding and the epigenetic landscape. Our results suggest that the AD-protective SPI1 haplotypes regulate pathways involved in immune and neuronal functions. CONCLUSION: This study is the first to report a significant association of SPI1 with AD in the Chinese population. It also identifies SPI1 haplotypes that are associated with SPI1 gene expression and decreased AD risk.
Overview
CoChat Summary
TL;DR
This study reports that SPI1 SNP rs3740688 and haplotypes β and γ are associated with reduced Alzheimer’s disease (AD) risk in a Hong Kong Chinese cohort, with haplotype γ also showing protective effects in APOE ε3 homozygous European-descent cohorts. The protective haplotypes are linked to decreased SPI1 expression in blood or brain and to immune/neuronal pathways.
Key findings
- In the Chinese cohort (333 AD, 721 controls), rs3740688 was significantly AD-protective (OR = 0.72 [0.58–0.89]; adjusted Beta = –0.326±0.109, p = 0.003; APOE-adjusted Beta = –0.350±0.113, p = 0.002).
- Haplotypes β (rs1057233–rs3740688) and γ (rs3740688–rs78245530) were AD-protective in Chinese participants (β: Beta = –0.337±0.118, p = 0.004; γ: Beta = –0.726±0.342, p = 0.034), with β remaining significant after APOE adjustment (Beta = –0.368±0.122, p = 0.003).
- In European-descent APOE33 participants, haplotype γ was AD-protective (Beta = –0.213±0.137, p = 0.030), and meta-analysis across Chinese and European APOE33 participants gave Beta = –0.248±0.133, p = 0.015, though this did not pass the multiple-testing threshold (0.05/6 = 0.0083).
- Haplotype γ was associated with delayed AD onset (HR = 0.54 [0.30–0.95], p = 0.035) and better MMSE performance (Beta = 0.173±0.066, p = 0.009) in APOE33 European-descent cohorts; it was also associated with decreased SPI1 expression in cortex (Beta = –0.447±0.166, p = 0.008) and frontal cortex (Beta = –0.361±0.174, p = 0.039), while haplotype β was associated with decreased SPI1 expression in blood (Beta = –0.119±0.060, p = 0.047) and strongly in monocytes/macrophages (p < 2×10–9).
Methods
- Genetic association analysis of three SPI1 SNPs (rs1057233, rs3740688, rs78245530) in a Hong Kong Chinese AD cohort (n = 333 AD, n = 721 normal controls), using TaqMan genotyping and whole-genome sequencing data.
- Replication and endophenotype analyses used European-descent AD cohorts (ADNI, ADC, LOAD; n = 5,094 AD, n = 4,663 controls) and expression datasets (GTEx, BRAINEAC, Cardiogenics), with haplotype-based logistic regression adjusted for age, sex, APOE, and principal components where applicable.
- Meta-analysis used METASOFT with random-effects and RE2 models; downstream analyses included Gene Ontology, protein–protein interaction networks, miRNA-binding prediction, and epigenetic annotation of SPI1 regulatory regions.
Limitations
- The paper states that larger cohorts and additional independent cohorts are needed to confirm the SPI1 haplotype–AD associations and their effects on age of onset and cognition, and that functional studies are needed to elucidate how haplotypes modulate SPI1 expression and microglial AD-associated functions.
- Evident from the text: the European-descent haplotype γ AD-protective effect was observed only in APOE33 participants, and the cross-population meta-analysis did not pass the multiple-testing correction threshold.
- Evident from the text: some key findings rely on public datasets and in silico/epigenetic annotations, and the homozygous haplotype γ carrier analysis in LOAD involved only n = 10 individuals.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
16 Valid · 3 Not valid · 9 Not checked · 71 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“genome-wide association studies (GWASs) suggest that SPI1—which encodes PU.1, a transcription factor that regulates the expression of immune-related genes in myeloid cells [7], is associated with AD [4–6].”
§ Association of SPI1 Haplotypes with Altered SPI1 Gene Expression and Alzheimer’s Disease Risk > INTRODUCTION
What the sources say
- Supportedcites [4] Kunkle, 2019, Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing, Nat Genet source
In Results, under “Candidate gene prioritization at genome-wide loci” (page not provided), the paper identifies an SPI1 locus and reports evidence that a variant affects both SPI1 expression and Alzheimer’s disease risk. This supports the hedged claim that GWAS findings suggest an association. (LLM, conf=0.90)
- Supportedcites [5] Huang, 2017, A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease, Nat Neurosci source
The Results section (‘Conditional and SMR analysis of the SPI1/CELF1 locus’) identifies SPI1 as the most likely gene underlying the association with Alzheimer’s disease at this locus. The Discussion likewise nominates SPI1 as the gene responsible for the disease association. Page numbers are not supplied in our copy. (LLM, conf=0.93)
- Could not verifycites [6] Marioni, 2018, GWAS on family history of Alzheimer’s disease, Transl Psychiatry sourceExperimental — accuracy not yet measured
The Results sections report Alzheimer’s-associated loci and genes, but the passages in our copy do not identify SPI1 among them. Searches for “SPI1” and “PU.1” found no passage addressing an association between SPI1 and Alzheimer’s disease. (LLM, conf=0.72)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“elevated brain SPI1 transcript level is associated with AD [8]”
§ Association of SPI1 Haplotypes with Altered SPI1 Gene Expression and Alzheimer’s Disease Risk > INTRODUCTION
What the sources say
- Partly supportedcites [8] Morabito, 2020, Integrative genomics approach identifies conserved transcriptomic networks in Alzheimer’s disease, Hum Mol Genet sourceExperimental — accuracy not yet measured
The Results sections on glial co-expression changes and genetic risk report that an upregulated, AD-associated microglial module contains SPI1. They do not establish that SPI1 transcript levels themselves are elevated in AD brain tissue; a module-level association does not demonstrate the direction of change for every member gene. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“suggesting it regulates SPI1 gene expression through altering the epigenetic landscape [6].”
§ Association of SPI1 Haplotypes with Altered SPI1 Gene Expression and Alzheimer’s Disease Risk > INTRODUCTION
What the sources say
- Could not verifycites [6] Marioni, 2018, GWAS on family history of Alzheimer’s disease, Transl Psychiatry sourceExperimental — accuracy not yet measured
The Results section on summary data-based Mendelian randomisation reports associations involving TOMM40 expression and DNA methylation, not SPI1. Searches for rs78245530 and SPI1-related epigenetic effects found no passage in our copy linking that variant to SPI1 expression or an altered epigenetic landscape. (LLM, conf=0.76)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“rs78245530 is associated with altered DNA methylation states in the frontal cortex”
§ Association of SPI1 Haplotypes with Altered SPI1 Gene Expression and Alzheimer’s Disease Risk > INTRODUCTION
What the sources say
- Could not verifycites [6] Marioni, 2018, GWAS on family history of Alzheimer’s disease, Transl Psychiatry sourceExperimental — accuracy not yet measured
The Methods and Results sections on summary data-based Mendelian randomisation describe methylation-QTL data from prefrontal cortex samples and report methylation associations, but do not link rs78245530 to methylation. A search for rs78245530 in our copy found no passage identifying that variant or supporting the claimed association. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It is unclear whether SPI1 genetic factors modulate AD risk in populations of non-European descent, as related studies have only been conducted in populations of European descent.”
§ Association of SPI1 Haplotypes with Altered SPI1 Gene Expression and Alzheimer’s Disease Risk > INTRODUCTION
What the sources say
- Partly supportedcites [4] Kunkle, 2019, Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing, Nat Genet sourceExperimental — accuracy not yet measured
The Results (Candidate gene prioritization at genome-wide loci; page unavailable) implicate SPI1 in an Alzheimer’s disease risk locus. The Methods (Pre-imputation genotype chip quality control; page unavailable) say that individuals with non-European ancestry were excluded, so this study does not establish whether the association applies to them. The paper does not establish the broader claim that all related studies were conducted only in populations of European descent. (LLM, conf=0.85)
- Partly supportedcites [5] Huang, 2017, A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease, Nat Neurosci sourceExperimental — accuracy not yet measured
Online Methods > Quality Control (page unavailable) states that individuals with evidence of non-European ancestry were excluded from this paper’s analyses. That supports uncertainty about whether its SPI1 findings apply to non-European populations, but the paper does not establish that all related studies were conducted only in European-descent populations. (LLM, conf=0.86)
- Could not verifycites [6] Marioni, 2018, GWAS on family history of Alzheimer’s disease, Transl Psychiatry sourceExperimental — accuracy not yet measured
The Genotyping methods state that the UK Biobank analysis excluded participants with non-British ancestry. But the paper does not address SPI1 genetic factors or say that related SPI1 studies have only involved populations of European descent. A search of our copy for SPI1 and ancestry terms did not establish the claim. (LLM, conf=0.77)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
56 more claims · 4 with their cited sources checked
Create a free account to see all 99 claims and every source verdict.
- It may state two separate claims as one. 22
- Probably not a substantial claim. 16
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Furthermore, the SNPs rs3740688 and rs78245530 are significantly associated with Alzheimer's disease in European [23] and Chinese [24] populations, respectively. Interestingly, these variants are also suggested to reduce the risk of developing Alzheimer's disease in these specific populations [23, 24].”
From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [24]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that reduced PU.1 expression is protective against AD (Cao et al., 2022; Huang et al., 2017)”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Cao et al., 2022
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“while polymorphisms in the PU.1 gene SPI1 that reduce PU.1 expression levels lower the risk of AD (Cao et al., 2022) and delay AD onset (Huang et al., 2017).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Cao et al., 2022
The cited source says what the claim attributes to it.
In the citing paper
“human SNPs that altered SPI1 expression level were reported to be associated with Alzheimer’s disease (AD) pathogenesis (Cao et al., 2022; Huang et al., 2017).”
From Pu.1/Spi1 dosage controls the turnover and maintenance of microglia in zebrafish and mammals (2025) · cites this paper as Cao et al., 2022
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259 · cited 1×
“We subjected significantly downregulated ( Beta < 0, p < 0.05) and upregulated ( Beta > 0, p 0.05) genes associated with SPI1 haplotypes to the enrichGO function from the clusterProfiler package in R [31].”
Influentialfastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721 · cited 1×
“subjected the raw reads to fastp for quality con145 trol, reads trimming, and filtration [11] and aligned 146”
Self-citationThe Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749 · cited 1×
“We subsequently queried the STRING database for the protein–protein interaction (PPI) network of genes enriched in different biological processes [32].”
Twelve years of SAMtools and BCFtools
Danecek, P., Bonfield, J. K., Liddle, J., Marshall, J., Ohan, V., Pollard, M. O., Whitwham, A., Keane, T., McCarthy, S. A., Davies, R. M., et al. (2021) · GigaScience · doi:10.1093/gigascience/giab008 · Cited by 15,343 · cited 1×
“Meanwhile, we obtained the haplotypes of Hong Kong Chinese WGS data or European descent cohort data from phased VCF files using the bcftools convert --hapsample function [26].”
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Cited by
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
“1 (SPI1), involved in the expression of immune-related genes in myeloid cells, could contribute to AD by regulating key pathways associated with the immune response and altering the epigenetic landscape [47,48].”
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
“SPI1 (Cao et al., 2022) rs1057233 Transcription factor PU.”
Insights into Alzheimer’s disease from single-cell genomic approaches
Murdock, M. H., & Tsai, L.-H. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01222-2 · Cited by 148
Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool
Romero-Molina, C., Garretti, F., Andrews, S. J., Marcora, E., & Goate, A. M. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.015 · Cited by 111
Ralvenius, W. T., Andresen, J. L., Huston, M. M., Penney, J., Bonner, J. M., Fenton, O. S., Langer, R., & Tsai, L. (2024) · Advanced Materials · doi:10.1002/adma.202309225 · Cited by 78
Metadata
- Authors
- Cao, H., Initiative, A. D. N., Zhou, X., Chen, Y., Ip, F. C. F., Chen, Y., Lai, N. C. H., Lo, R. M. N., Tong, E. P. S., Mok, V. C. T., Kwok, T. C. Y., Fu, A. K. Y., & Ip, N. Y.
- Affiliations
- Hong Kong University of Science and Technology (HK)
- Chinese Academy of Sciences (CN)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Ip, Nancy Y.
- ORCID
- Venue
- Journal of Alzheimer s Disease
- Publisher
- SAGE Publications
- Published
- 2022-04-19
- Volume
- 86
- Issue
- 4
- Pages
- 1861-1873
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC9108557
- OpenAlex
- W4214632026
- Semantic Scholar
- 157c7995870ade5d6e1ffeb8169887063a4e79b9
- Cited by
- 29
- References
- 53
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 7 · 2023: 6 · 2022: 1
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- Alzheimer's Disease Neuroimaging Initiative
- National Natural Science Foundation of China (32061160472, 2018B030336001, 2019003, 2018YFE0203600, 2019B1515130004, 2019001)
- University Grants Committee (T13-607/12R, AoE/M-604/16)
- Innovation and Technology Commission (ITC PD/17-9)
- Shenzhen Knowledge Innovation Program (JCYJ20180507183642005)
- National Institute on Aging
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- PU.1, Alzheimer's disease
- MeSH terms
- Proto-Oncogene Protein Spi-1, Alzheimer Disease, China, Haplotypes, Humans, Proto-Oncogene Proteins, Trans-Activators, Gene Expression, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of SPI1 Haplotypes with Altered SPI1 Gene Expression and Alzheimer’s Disease Risk. https://app.cochat.ai/papers/10.3233/jad-215311
- The paper
- Cao, H., Initiative, A. D. N., Zhou, X., Chen, Y., Ip, F. C. F., Chen, Y., Lai, N. C. H., Lo, R. M. N., Tong, E. P. S., Mok, V. C. T., Kwok, T. C. Y., Fu, A. K. Y., & Ip, N. Y. (2022). Association of SPI1 Haplotypes with Altered SPI1 Gene Expression and Alzheimer’s Disease Risk. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-215311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.